Moderna's shares rose by 2.9% in pre-market trading as they rebounded from a recent decline. This follows a significant rally triggered by positive Phase 3 trial results for its p…
Moderna's stock experienced a significant increase of more than 90% in premarket trading after the company announced positive results from a Phase 3 trial of its personalized mRNA…
BioNTech SE's stock fell by 8% after the company halted its Phase 2 colorectal cancer vaccine trial due to futility. This decision has also affected other mRNA vaccine stocks, inc…
On August 19, 2026, Wall Street rebounded from a three-day decline as Treasury yields fell following an announcement from the US Treasury Department regarding increased purchases…